Publications by authors named "F Cetani"
Article Synopsis
- Aberrant epigenetic changes, specifically in DNA methylation and non-coding RNAs, play a significant role in the development of parathyroid tumors, particularly concerning the genes RASSF1A and APC, which are often downregulated in cancers.
- In a study of parathyroid adenomas and carcinomas, RASSF1A promoter methylation was found in approximately 90% of adenomas and was inversely related to tumor size; however, APC methylation appeared less frequently.
- The research concluded that the methylation of RASSF1A and APC is a common feature in parathyroid tumors, with the activity of DNA methyltransferases affecting
Skeletal phenotypes in postmenopausal women affected by primary hyperparathyroidism.
Front Endocrinol (Lausanne)
November 2024
Purpose: The current primary hyperparathyroidism (PHPT) presents as a mild disease. We explored skeletal phenotypes in postmenopausal women affected by PHPT, focusing on fracture prevalence.
Methods: PHPT women were retrospectively evaluated at four Italian centers for osteoporosis management (two centers in Milan, = 244; Cuneo, = 128; Pisa, = 131).
Background: Brown tumors are rare bone manifestations of primary hyperparathyroidism (PHPT) that may occur at different sites either as single or multiple lesions and they can easily be mistaken for malignant lesions. Neither bone site nor morphological or functional imaging are useful to drive the differential diagnosis and biopsy is often the only conclusive procedure.
Case Description: We report the case of a 53 years-old man referred to our outpatient clinic for severe symptomatic PHPT complicated by nephrolithiasis and osteoporosis.
Background: Parathyroid gland (PG) surgery is often challenging due to the small size and indistinct nature of these glands. The introduction of intraoperative near-infrared autofluorescence (NIRAF) has shown promise in localizing parathyroid tissue. However, the NIRAF features of parathyroid adenomas remain unclear.
View Article and Find Full Text PDFArticle Synopsis
- Conventional therapy for hypoparathyroidism helps with hypocalcemia symptoms but doesn't fix low parathyroid hormone (PTH) levels; TransCon PTH (palopegteriparatide) is being studied as a potential long-term treatment.
- A Phase 3 trial involved 82 adults across 21 sites in North America and Europe, with participants receiving TransCon PTH daily during a 156-week open-label period after an initial 26-week placebo-controlled phase.
- Results showed that by week 52, 81% of participants achieved normal serum calcium levels without needing conventional therapy, improved their quality of life, and experienced mostly mild to moderate side effects, indicating the treatment's sustained efficacy and safety.